Circulating Levels of Selenium and Zinc in Relation to Nutritional Status in Patients With Head and Neck Cancer

Westin, Thomas; Ahlbom, Eva; Johansson, Elisabeth; Sandström, Brittmarie; Karlberg, Ingvar; Edström, Staffan

doi:10.1001/archotol.1989.01860330069019

Cited by 33 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Low circulating concentrations of zinc have been associated with a catabolic state and an increased frequency of cancer cachexia. 16 Zinc deficiency may have implications in dogs with cancer similar to those observed in people, including cachexia and intolerance to cancer treatment regimens. Canine cancer patients may benefit from zinc supplementation during therapy, especially those with low serum concentrations or those suffering from immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Zinc, Chromium, and Iron Concentrations in Dogs with Lymphoma and Osteosarcoma

Kazmierski¹,

Ogilvie²,

Fettman³

et al. 2001

Veterinary Internal Medicne

View full text Add to dashboard Cite

We compared serum concentrations of zinc, chromium, and iron in dogs with cancer to those of normal dogs. Dogs with lymphoma (n = 50) and osteosarcoma (n = 52) were evaluated. Dogs with lymphoma had significantly lower (P = .0028) mean serum zinc concentrations (mean +/- SD; 1.0 +/- 0.3 mg/L) when compared to normal dogs (1.2 +/- 0.4 mg/L). Dogs with osteosarcoma also had lower mean serum zinc concentrations (1.1 +/- 0.4 mg/L), but this difference was not significant (P = .075). Serum chromium concentrations were significantly lower in dogs with lymphoma (2.6 +/- 2.6 microg/L, P = .0007) and osteosarcoma (2.4 +/- 3.1 microg/L, P = .0001) compared to normal dogs (4.7 +/- 2.8 microg/L). Serum iron concentrations and total iron-binding capacity were significantly lower in dogs with lymphoma (110.8 +/- 56.7 microg/dL, P < .0001, and 236.6 +/- 45.6 microg/dL, P < .0001, respectively) and osteosarcoma (99.6 +/- 49.3 microg/dL, P < .0001, and 245.0 +/- 43.8 microg/dL, P = .0011, respectively) when compared to normal dogs (175.1 +/- 56.7 microg/dL and 277.1 +/- 47.4 microg/dL). Mean ferritin concentration was significantly higher in dogs with lymphoma (1291.7 +/- 63.0 microg/L) than in normal dogs (805.8 +/- 291.1 microg/L, P < .0001) and dogs with osteosarcoma (826.5 +/- 309.2 microg/L, P < .0001). Further investigation is needed to explore the clinical significance of these mineral abnormalities in dogs with cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Alternatively, zinc status may be evaluated with zinc concentrations in lymphocytes and granulocytes, which is a standard practice in human patients. 16 Contamination of serum samples by zinc-containing rubber stoppers of vacutainer collection tubes also is a concern. 18 This contamination may falsely increase serum zinc concentration.…”

Section: Discussionmentioning

confidence: 99%

Serum Zinc, Chromium, and Iron Concentrations in Dogs with Lymphoma and Osteosarcoma

Kazmierski¹,

Ogilvie²,

Fettman³

et al. 2001

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…There are limited published information on associations of selenium and specific colon cancer stages. Weight loss is also of potential importance because decreased energy intake or possible disease-related metabolic changes resulting in weight loss could lead to lower selenium levels 36. Weight loss is a common symptom of colorectal cancer and, thus, an important factor to take into account 37…”

Section: Introductionmentioning

confidence: 99%

Selenium, Folate, and Colon Cancer

Connelly-Frost

Poole

Satia

et al. 2009

Nutrition and Cancer

View full text Add to dashboard Cite

Background-Selenium is an essential trace element which has been implicated in cancer risk; however, study results have been inconsistent with regard to colon cancer. Our objectives were to 1) investigate the association between selenium and colon cancer 2) evaluate possible effect measure modifiers and 3) evaluate potential biases associated with the use of post-diagnostic serum selenium measures

show abstract

“…Studies have shown that the daily dietary intake of Zn in Turkey has been in general below the recommended daily allowance values (22–25), and there has been a decrease in the mean plasma and serum Zn levels of head and neck cancer patients compared with normal controls (26–29). Zn deficiency has also been reported in a number of malignancies (21,26,30–32).…”

Section: Introductionmentioning

confidence: 99%

The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: A prospective, randomised, placebo-controlled study

Ertekin

Koç

Karslıoğlu

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

The purpose was to determine the effects of oral zinc sulphate along with radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer. Thirty patients with head and neck cancer were randomly assigned to receive either zinc sulphate capsules (including 50 mg zinc) (n = 15) or placebo (n = 15) three times a day, starting on the day of the first radiotherapy fraction and continuing throughout the scheduled radiotherapy course including weekends and 6 weeks after radiotherapy. The patients were treated with telecobalt radiation at conventional fractionation of 2 Gy/fraction and five fractions/ week in 20-35 fractions for a period of 4-7 weeks. Blood samples for biochemical parameters were collected after an overnight fast (12 h) before radiotherapy, the first day and 6 weeks after radiotherapy. In the placebo group, three patients were excluded. No difference was detected in any final measurement activities of erythrocyte anti-oxidant enzyme such as copper-zinc superoxide dismutase (Cu-Zn SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in the direct comparison between the zinc sulphate and the placebo group, except erythrocyte SOD activities measured the first day after radiotherapy (p < 0.03). In the respective measurement analysis of the groups in themselves, in the zinc sulphate group, while the statistical analysis for the activities of erythrocyte CAT and GSH-Px were significantly different (chi2 = 12.4, p < 0.05; chi2 = 8.9, p < 0.05, respectively) before radiotherapy, the first day and 6 weeks after radiotherapy, the activities of SOD did not differ (chi2 = 4.2, p > 0.05). In these three measurements, there was no statistical significance in the activities of enzymes in erythrocyte Cu-Zn SOD, CAT and GSH-Px in the placebo group. Before radiotherapy, plasma zinc levels were normal in 16 patients (59.2%) and were lower in 11 patients (40.8%) compared with laboratory levels. It would be worthwhile studying the effect of oral zinc sulphate supplements to improve the anti-oxidant enzyme activity in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.

show abstract

Circulating Levels of Selenium and Zinc in Relation to Nutritional Status in Patients With Head and Neck Cancer

Cited by 33 publications

References 16 publications

Serum Zinc, Chromium, and Iron Concentrations in Dogs with Lymphoma and Osteosarcoma

Serum Zinc, Chromium, and Iron Concentrations in Dogs with Lymphoma and Osteosarcoma

Selenium, Folate, and Colon Cancer

The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: A prospective, randomised, placebo-controlled study

Contact Info

Product

Resources

About